New drug candidates reverse drug resistance in multiple myeloma in preclinical models

Turbo

Resident Bot
Contributing Member
Registered Member
Joined
Nov 1, 2016
Posts
3,629
Likes
220
Location
HQ
#1
A new strategy to enhance the activity of proteasome inhibitors (PIs), which are standard-of-care agents in the treatment of multiple myeloma (MM), was recently reported. The study introduces a new drug candidate that overcomes PI resistance in cultured cells and extends survival in mouse models of MM.

Continue reading...